0000899866-20-000018.txt : 20200303
0000899866-20-000018.hdr.sgml : 20200303
20200303181658
ACCESSION NUMBER: 0000899866-20-000018
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200228
FILED AS OF DATE: 20200303
DATE AS OF CHANGE: 20200303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Franchini Indrani Lall
CENTRAL INDEX KEY: 0001708764
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-27756
FILM NUMBER: 20684508
MAIL ADDRESS:
STREET 1: C/O ALEXION PHARMACEUTICALS, INC
STREET 2: 100 COLLEGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000899866
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133648318
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 121 SEAPORT BOULEVARD
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 4752302596
MAIL ADDRESS:
STREET 1: 121 SEAPORT BOULEVARD
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: ALEXION PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19960111
4
1
wf-form4_158327740132826.xml
FORM 4
X0306
4
2020-02-28
0
0000899866
ALEXION PHARMACEUTICALS, INC.
ALXN
0001708764
Franchini Indrani Lall
C/O ALEXION PHARMACEUTICALS, INC.
121 SEAPORT BOULEVARD
BOSTON
MA
02210
0
1
0
0
EVP, Chief Compliance Officer
Common Stock, par value $.0001 per share
2020-02-28
4
A
0
9520
0
A
37741
D
Common Stock, par value $.0001 per share
2020-03-02
4
F
0
1267
90.54
D
36474
D
Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date.
This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.48 - $92.39. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
/s/ Douglas J. Barry, Attorney-in-Fact for Indrani L. Franchini
2020-03-03